• Title/Summary/Keyword: A protein-polyaccharide fraction

Search Result 2, Processing Time 0.016 seconds

An antitumor component of laetiporus sulphureus and its immunostimulating activity

  • Kang, Chang-Yuil;Lee, Chong-Ock;Chung, Kyeong-Soo;Choi, Eung-Chil;Kim, Byong-Kak
    • Archives of Pharmacal Research
    • /
    • v.5 no.2
    • /
    • pp.39-43
    • /
    • 1982
  • A protein-polysaccharide fraction was prepared from the carpophores of Laetiporus sulphureus. This fraction suppressed growth of sarcoma 180 in A-strain mice when administered i. p. To investigate the mechanism of antitumor action of this fraction, plaque assay was conducted by administrating i. p. to the mise at a dose level of 50mg/kg for five days. Ten days later, the mice were immunized with 1 * 10$^{7}$ sheep red blooc cells. The number of hemolytic plaque forming cells was significantly greater than that of the control mice. Three monosaccharides and fifteen amino acids were identified in the protein-polysaccharide fraction.

  • PDF

Flow Cytometrical Analysis of the Antitumor and Immunomodulatory Activities of GLB-A and GLB-B, the Protein-polysaccharide Fractions of the Growing Tips of Ganoderma Lucidum (영지버섯 생장점 단백다당체 GLB-A, GLB-B의 항암효과 및 면역 활성에 관한 유세포 분석학적 연구)

  • Oh, Jung-Yeon;Chung, Kyeong-Soo
    • YAKHAK HOEJI
    • /
    • v.42 no.5
    • /
    • pp.487-493
    • /
    • 1998
  • In the previous study we described the antitumor effect of GLB, a protein-polysaccharide fraction separated from the growing tips of Ganoderma lucidum, against sarcoma 18 0 solid tumor in ICR mice. In this study, we separated an acidic protein-polysaccharide fraction, GLB-A, and a basic protein-polyaccharide fraction, GLB-B, from GLB by differential precipitation, and elucidated their antitumor and immunomodulatory activities. When ip injected at the dose of 50mg/kg/day into the ICR mice, GLB-A and GLB-B inhibited the growth of ip implantated sarcoma 180 cells by 32.4% and 21.0%, respectively. Of these, GLB-A increased the % lymphoblast in the spleen of the tumor-bearing and the normal mice by 20.9% and 123.0%, and the CD4/CD8 ratio by 73.3% and 22.4%, respectively. GLB-A also increased the expression of CD25 (IL-2 receptor alpha ch0ain) in normal mice by 82.0%. These results strongly suggest that GLB-A is a promising candidate for antitumor immunomodulatory medicine.

  • PDF